{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:23:57Z","timestamp":1782923037648,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>BRAF alterations are uncommon in chronic lymphocytic leukemia (CLL), yet increasing use of broad genomic profiling has identified them as a recurrent component of MAPK-pathway dysregulation. This revised review summarizes the reported frequency, mutation spectrum, co-mutation patterns, treatment-era associations, and clinical implications of BRAF alterations in adult CLL, with explicit separation of chemoimmunotherapy-dominant cohorts from targeted-therapy-era cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Across published studies, BRAF mutations are usually detected in approximately 2\u20136% of unselected CLL cohorts, with higher frequencies in biologically enriched or treatment-selected populations. In chemoimmunotherapy-dominant cohorts, the clinically relevant signals are more often seen in treatment-timing endpoints such as time to first treatment, treatment-free survival, or time to next treatment than in overall survival alone. In targeted-therapy-era studies, including phase II and real-world cohorts, BRAF alterations recur as part of MAPK-pathway\u2013driven clonal evolution at relapse after BTK-, PI3K-, or BCL2-directed therapy. Small pathology-based series also suggest that BRAF V600E is more frequent in Richter transformation than in untransformed CLL. By contrast, direct evidence for BRAF inhibitors in CLL is very limited, and available preclinical data do not support routine single-agent BRAF inhibition for the predominantly non-V600E lesions seen in CLL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current evidence supports interpreting BRAF-mutated CLL within the broader RAS\u2013RAF\u2013MAPK\u2013ERK signaling context rather than as a classical V600E-driven entity. At present, BRAF is best viewed as a biologic and resistance-relevant annotation rather than an established standalone prognostic biomarker or routine therapeutic target. Its clinical relevance appears greatest in trisomy 12-enriched disease, genomically complex cases, Richter transformation with V600E lesions, and treatment-exposed relapse where pathway-directed strategies may become increasingly important.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11899-026-00780-7","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:26:13Z","timestamp":1777602373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance"],"prefix":"10.1007","volume":"21","author":[{"given":"Abdulrahman","family":"Al-Abdulmalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulgayoom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Abdullah","family":"Dalol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassam","family":"Muthanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"780_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","volume":"152","author":"DA Landau","year":"2013","unstructured":"Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152:714\u201326. https:\/\/doi.org\/10.1016\/j.cell.2013.01.019.","journal-title":"Cell"},{"key":"780_CR2","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1014209.","journal-title":"N Engl J Med"},{"key":"780_CR3","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood-2010-04-279083","volume":"116","author":"G Badalian-Very","year":"2010","unstructured":"Badalian-Very G, Vergilio J-A, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919\u201323. https:\/\/doi.org\/10.1182\/blood-2010-04-279083.","journal-title":"Blood"},{"key":"780_CR4","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1182\/bloodadvances.2024014206","volume":"9","author":"JR Brown","year":"2025","unstructured":"Brown JR, Li J, Eichhorst BF, et al. Acquired mutations in patients with relapsed\/refractory CLL who progressed in the ALPINE study. Blood Adv. 2025;9:1918\u201326. https:\/\/doi.org\/10.1182\/bloodadvances.2024014206.","journal-title":"Blood Adv"},{"key":"780_CR5","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/1078-0432.CCR-22-3934","volume":"30","author":"N Jain","year":"2024","unstructured":"Jain N, Croner LJ, Allan JN, et al. Absence of BTK, BCL2, and PLCG2 mutations in chronic lymphocytic leukemia relapsing after first-line treatment with fixed-duration ibrutinib plus venetoclax. Clin Cancer Res. 2024;30:498\u2013505. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3934.","journal-title":"Clin Cancer Res"},{"key":"780_CR6","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio S, Sutton L-A, Ljungstr\u00f6m V, et al. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023;7:2794\u2013806. https:\/\/doi.org\/10.1182\/bloodadvances.2022008821.","journal-title":"Blood Adv"},{"key":"780_CR7","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.3324\/haematol.2022.281869","volume":"108","author":"A L\u00fctge","year":"2023","unstructured":"L\u00fctge A, Lu J, H\u00fcllein J, et al. Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia. Haematologica. 2023;108:2664\u201376. https:\/\/doi.org\/10.3324\/haematol.2022.281869.","journal-title":"Haematologica"},{"key":"780_CR8","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/ajh.26578","volume":"97","author":"C P\u00e9rez-Carretero","year":"2022","unstructured":"P\u00e9rez-Carretero C, Hern\u00e1ndez-S\u00e1nchez M, Gonz\u00e1lez T, et al. TRAF3 alterations are frequent in del-3\u2032IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol. 2022;97:903\u201314. https:\/\/doi.org\/10.1002\/ajh.26578.","journal-title":"Am J Hematol"},{"key":"780_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1182\/blood.2020006765","volume":"138","author":"I Murali","year":"2021","unstructured":"Murali I, Kasar S, Naeem A, et al. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. Blood. 2021;138:44\u201356. https:\/\/doi.org\/10.1182\/blood.2020006765.","journal-title":"Blood"},{"key":"780_CR10","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/ijc.33235","volume":"147","author":"C P\u00e9rez-Carretero","year":"2020","unstructured":"P\u00e9rez-Carretero C, Hern\u00e1ndez-S\u00e1nchez M, Gonz\u00e1lez T, et al. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. Int J Cancer. 2020;147:2780\u201392. https:\/\/doi.org\/10.1002\/ijc.33235.","journal-title":"Int J Cancer"},{"key":"780_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.exphem.2019.02.003","volume":"72","author":"M Hern\u00e1ndez-S\u00e1nchez","year":"2019","unstructured":"Hern\u00e1ndez-S\u00e1nchez M, Rodr\u00edguez-Vicente AE, Gonz\u00e1lez-Gasc\u00f3n Y Mar\u00edn I, et al. DNA damage response-related alterations define the genetic background of patients with chronic lymphocytic leukemia and chromosomal gains. Exp Hematol. 2019;72:9\u201313. https:\/\/doi.org\/10.1016\/j.exphem.2019.02.003.","journal-title":"Exp Hematol"},{"key":"780_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3324\/haematol.2018.196931","volume":"104","author":"N Gim\u00e9nez","year":"2019","unstructured":"Gim\u00e9nez N, Mart\u00ednez-Trillos A, Montraveta A, et al. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica. 2019;104:576\u201386. https:\/\/doi.org\/10.3324\/haematol.2018.196931.","journal-title":"Haematologica"},{"key":"780_CR13","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1038\/s41375-019-0444-6","volume":"33","author":"E Vendramini","year":"2019","unstructured":"Vendramini E, Bomben R, Pozzo F, et al. KRAS, NRAS, and BRAF mutations are highly enriched in trisomy 12 chronic lymphocytic leukemia and are associated with shorter treatment-free survival. Leukemia. 2019;33:2111\u20135. https:\/\/doi.org\/10.1038\/s41375-019-0444-6.","journal-title":"Leukemia"},{"issue":"1","key":"780_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","volume":"9","author":"CD Herling","year":"2018","unstructured":"Herling CD, Abedpour N, Weiss J, et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018;9:727. https:\/\/doi.org\/10.1038\/s41467-018-03170-7.","journal-title":"Nat Commun"},{"key":"780_CR15","doi-asserted-by":"publisher","first-page":"6217","DOI":"10.1158\/1078-0432.CCR-15-2903","volume":"22","author":"T Pandzic","year":"2016","unstructured":"Pandzic T, Larsson J, He L, et al. Transposon mutagenesis reveals fludarabine resistance mechanisms in chronic lymphocytic leukemia. Clin Cancer Res. 2016;22:6217\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2903.","journal-title":"Clin Cancer Res"},{"key":"780_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjh.13291","volume":"170","author":"RS Sellar","year":"2015","unstructured":"Sellar RS, Fend F, Akarca AU, et al. BRAF(V600E) mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. Br J Haematol. 2015;170:282\u20135. https:\/\/doi.org\/10.1111\/bjh.13291.","journal-title":"Br J Haematol"},{"key":"780_CR17","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","volume":"4","author":"F Damm","year":"2014","unstructured":"Damm F, Mylonas E, Cosson A, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4:1088\u2013101. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0104.","journal-title":"Cancer Discov"},{"key":"780_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.3109\/10428194.2012.742525","volume":"54","author":"BMC Jebaraj","year":"2013","unstructured":"Jebaraj BMC, Kienle D, B\u00fchler A, et al. BRAF mutations in chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1177\u201382. https:\/\/doi.org\/10.3109\/10428194.2012.742525.","journal-title":"Leuk Lymphoma"},{"key":"780_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.leukres.2011.12.015","volume":"36","author":"SE Langabeer","year":"2012","unstructured":"Langabeer SE, Quinn F, O\u2019Brien D, et al. Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res. 2012;36:483\u20134. https:\/\/doi.org\/10.1016\/j.leukres.2011.12.015.","journal-title":"Leuk Res"},{"key":"780_CR20","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1038\/s41375-020-0713-6","volume":"34","author":"SJ Blakemore","year":"2020","unstructured":"Blakemore SJ, Clifford R, Parker H, et al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial. Leukemia. 2020;34:1760\u201374. https:\/\/doi.org\/10.1038\/s41375-020-0713-6.","journal-title":"Leukemia"},{"key":"780_CR21","doi-asserted-by":"publisher","first-page":"5074","DOI":"10.1172\/JCI76539","volume":"124","author":"N Yaktapour","year":"2014","unstructured":"Yaktapour N, Meiss F, Mastroianni J, et al. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. J Clin Invest. 2014;124:5074\u201384. https:\/\/doi.org\/10.1172\/JCI76539.","journal-title":"J Clin Invest"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00780-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-026-00780-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-026-00780-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:26:13Z","timestamp":1777602373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-026-00780-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1007\/s11899-026-00780-7","relation":{},"ISSN":["1558-822X"],"issn-type":[{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Qatar National Library will cover the open access publication charges","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgement"}},{"value":"was not required for this study, as it is based exclusively on published literature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}